NCT06393673
Not yet recruiting
Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
Hansoh BioMedical R&D Company1 site in 1 country195 target enrollmentMay 30, 2024
ConditionsVasomotor Symptoms
Overview
- Phase
- Phase 2
- Intervention
- HS-10384 tablet Dose 1
- Conditions
- Vasomotor Symptoms
- Sponsor
- Hansoh BioMedical R&D Company
- Enrollment
- 195
- Locations
- 1
- Primary Endpoint
- Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4;
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.
Detailed Description
The phase 2 study is consisted with 2 doses. The aim is to detect the efficacy, safety, pharmacokinetics and pharmacodynamics characteristics of HS-10384 in participants with vasomotor symptoms.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women between 40 and 65 years old (including extremes);
- •The body mass index at screening is between 18.5\~30 kg/m2 (including extremes)；
- •Subjects are postmenopausal women at screening as qualified by any of the following criteria: spontaneous amenorrhea ≥ 12 months, or spontaneous amenorrhea ≥ 6 months and FSH\>40 IU/L (without other obvious pathological or physiological reasonsbefore screening), or documented surgical sterilization (such as hysterectomy, bilateral salpingectomy or bilateral oophorectomy, etc.);
- •At least 50 moderate to severe vasomotor symptoms per week (ie, 7 consecutive days), or 7 moderate to severe vasomotor symptoms per day (ie, 7 consecutive days) recorded in the daily diary during the screening period;
- •The blood pregnancy test of female subjects at baseline period is negative.
Exclusion Criteria
- •Participants with disease history of unexplained uterine bleeding, endometrial hyperplasia, ovarian tumor, pituitary tumor, or other diseases evaluated by the principal investigator as not suitable for this study;
- •Have a history of migraine within 3 months before screening;
- •Uncontrolled hypertension and a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg;
- •Previous or current history of a malignant tumor, except for basal cell carcinoma;
- •Participants with clinically significant diseases (such as neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, skeletal muscle system, endocrine and metabolic system, blood system, skin disease, immune system, tumor, etc.) were evaluated by the researcher as not suitable for this study;
- •Within 4 weeks or 5 half-lives (whichever is longer) before taking drug, participants have taken hormonal treatment, hormonal contraceptive or other therapy due to VMS;
- •Within 4 weeks or 5 half-lives (whichever is longer) before screening, and during the whole study period, it is expected to take any medicine and health care products, including prescription drugs, immunomodulator or Chinese herbal medicine, etc.;
- •Participants have participated in any interventional study or taken study drugs within 3 months before screening;
- •Judged by the Investigator to be unsuited to participate in the study based on findings observed during physical examination, vital sign assessment, or 12-lead electrocardiogram (ECG), et al.;
- •Active liver disease or jaundice, or values of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x the upper limit of normal (ULN); or total bilirubin or direct bilirubin \>1.5 x ULN;
Arms & Interventions
HS-10384 Dose 1
Dose level 1 of HS-10384
Intervention: HS-10384 tablet Dose 1
HS-10384 Dose 1
Dose level 1 of HS-10384
Intervention: HS-10384-matched placebo tablets
HS-10384 Dose 2
Dose level 2 of HS-10384
Intervention: HS-10384 tablet Dose 2
HS-10384 Dose 2
Dose level 2 of HS-10384
Intervention: HS-10384-matched placebo tablets
Placebo
Intervention: HS-10384-matched placebo tablets
Outcomes
Primary Outcomes
Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4;
Time Frame: Baseline to Week 4
Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 4;
Time Frame: Baseline to Week 4
Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 12.
Time Frame: Baseline to Week 12
Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 12;
Time Frame: Baseline to Week 12
Secondary Outcomes
- Mean change in the hot flash score of moderate and severe vasomotor symptoms from baseline to each study week;(Baseline to Week 15)
- Number of participants with clinical laboratory abnormalities;(Baseline to Week 15)
- Number of participants with abnormalities of physical examinations(Baseline to Week 15)
- Change from baseline in ECG parameters(Baseline to Week 15)
- Change from baseline in plasma bone density marker concentrations(Baseline to Week 15)
- Change from baseline in Endometrial health assessment.(Baseline to Week 15)
- Number of participants with abnormalities of vital signs(Baseline to Week 15)
- Mean change in the severity of moderate and severe vasomotor symptoms from baseline to each study week;(Baseline to Week 15)
- Mean change in the frequency of moderate and severe vasomotor symptoms from baseline to each study week;(Baseline to Week 15)
- Mean percent reduction of 50% and 100% of moderate and severe vasomotor symptoms from baseline to each study week.(Baseline to Week 15)
- Incidence and severity of treatment-emergent adverse events;(Baseline to Week 15)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 InfectionCOVID-19 InfectionNCT05752175Westlake Pharmaceuticals (Hangzhou) Co., Ltd.80
Completed
Phase 2
The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection FractionCardiac FailureNCT02932566Manchester University NHS Foundation Trust129
Completed
Phase 2
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)Hypertension, PulmonaryNCT04945460Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA164
Not yet recruiting
Phase 2
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip OsteoarthritisDegenerative OsteoarthritisNCT05276011Kolon TissueGene, Inc.255
Completed
Phase 1
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)Influenza InfectionNCT05818124Merck Sharp & Dohme LLC161